SYNTHETIC CONJUGATED ESTROGENS A (estrogens, conjugated synthetic a) by Teva is clinical pharmacology endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. First approved in 2008.
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
Synthetic Conjugated Estrogens A is a hormone replacement therapy (HRT) product administered as a vaginal cream containing synthetic conjugated estrogens that mimic endogenous estrogen metabolism. It works by binding to estrogen receptors in target tissues to maintain female reproductive system function and reduce postmenopausal symptoms. The product is indicated for postmenopausal women experiencing estrogen deficiency.
Product approaching end-of-life with declining market exclusivity; expect smaller, maintenance-focused brand teams and potential consolidation within HRT portfolios.
CLINICAL PHARMACOLOGY Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal…
Worked on SYNTHETIC CONJUGATED ESTROGENS A at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Teva is hiring 1 role related to this product
Working on Synthetic Conjugated Estrogens A offers limited career acceleration due to the product's LOE-approaching status and minimal linked job openings. Roles focus on maintaining market share in a declining franchise rather than driving innovation or expansion.